AIMT
Aimmune Therapeutics
AIMT
AIMT
Delisted
AIMT was delisted on the 12th of October, 2020.
165 hedge funds and large institutions have $824M invested in Aimmune Therapeutics in 2020 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 72 increasing their positions, 37 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
2% more funds holding
Funds holding: 161 → 165 (+4)
Holders
165
Holding in Top 10
1
Calls
$8.66M
Puts
$5.11M
Top Buyers
| 1 | +$25.5M | |
| 2 | +$17.1M | |
| 3 | +$5.41M | |
| 4 |
SCA
Southpoint Capital Advisors
New York
|
+$5.01M |
| 5 |
BlackRock
New York
|
+$4.95M |
Top Sellers
| 1 | -$28.5M | |
| 2 | -$12.9M | |
| 3 | -$11.1M | |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$11M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$7.88M |